TNF Pharmaceuticals (NASDAQ:TNFA) Stock Price Down 1.3% – What’s Next?

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA)’s stock price dropped 1.3% on Friday . The stock traded as low as $3.75 and last traded at $3.92. Approximately 237,138 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 3,511,287 shares. The stock had previously closed at $3.97.

TNF Pharmaceuticals Trading Down 1.3%

The company has a market cap of $7.24 million, a price-to-earnings ratio of -0.02 and a beta of 2.04. The firm’s fifty day simple moving average is $4.65 and its 200 day simple moving average is $5.18.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.